Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

New Indication Alert: MSD’s Keytruda® Plus Chemo FDA-Approved for MPM

Sep 18, 2024

On 18 September 2024, Merck (known as MSD outside the US and Canada) announced that Keytruda® (pembrolizumab) has been approved by the FDA, in combination with pemetrexed and platinum chemotherapy, for first-line treatment of adults with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).  MSD’s sBLA for this indication of was accepted for priority review by the FDA in May 2024, with a target action date of 25 September 2024.

MSD currently has an application before Australia’s TGA for the same MPM indication expansion for Keytruda®.

The new US indication follows Keytruda®’s FDA approval in June 2024 (in combination with carboplatin and paclitaxel) for primary advanced or recurrent endometrial carcinoma.